共 59 条
[1]
Karmali KN(2015)Global, regional, and national comparative risk assessment of 79 behavioral, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 Lancet 386 2287-323
[2]
Lloyd-Jones DM(2016)Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews JAMA Cardiol 1 341-9
[3]
Berendsen MA(2014)2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2889-2934
[4]
Goff DC(2013)ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals J Am Heart Assoc 2016 5(8)-94
[5]
Sanghavi DM(2015)A new approach to test validity and clinical usefulness of the 2013 ACC/AHA guideline on statin therapy: A population-based study Int J Cardiol 184 587-81
[6]
Brown NC(2016)Individualized statin benefit for determining statin eligibility in the primary prevention of cardiovascular disease Circulation 133 1574-90
[7]
Stone NJ(2012)The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomized trials Lancet 380 581-31
[8]
Robinson JG(2016)Cholesterol lowering in intermediate-risk persons without cardiovascular disease N Engl J Med 374 2021-20
[9]
Lichtenstein AH(2016)Blood-pressure lowering in intermediate-risk persons without cardiovascular disease N Engl J Med 374 2009-43
[10]
Bairey Merz CN(2016)Blood-pressure and cholesterol lowering in persons without cardiovascular disease N Engl J Med 374 2032-14